This content is machine translated RMS and PPMS Early therapy with ocrelizumab slows the disease More than 100,000 people with MS are being treated with ocrelizumab worldwide. New analysis shows that drug exposure and low B-cell levels reduce the risk of progression. Long-term data advise…
